Thermo Fisher Scientific Files 8-K on Debt Offerings

TL;DR

TMO filed an 8-K detailing various senior notes due between 2026-2039.

AI Summary

Thermo Fisher Scientific Inc. filed an 8-K on October 29, 2025, reporting on various financial instruments including common stock and multiple series of senior notes due between 2026 and 2039. The filing details the issuance and terms of these debt instruments, which are crucial for the company's ongoing financing and operational activities.

Why It Matters

This filing provides insight into Thermo Fisher Scientific's capital structure and financing activities, which can impact its financial flexibility and investment capacity.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of financial instruments and does not indicate any immediate operational or financial distress.

Key Numbers

• 2026-2039 — Senior Notes Maturity Dates (Indicates the range of maturity for various debt issuances.)

Key Players & Entities

• THERMO FISHER SCIENTIFIC INC. (company) — Filer
• 0000097745 (company) — Central Index Key
• 042209186 (company) — EIN
• 20251029 (date) — Filing Date

FAQ

Key Financial Figures

• $1.00 — ange on which registered Common Stock, $1.00 par value TMO New York Stock Exchange
• $8.875 billion — ings, Inc. ("Clario") for approximately $8.875 billion in cash at the closing of the transacti
• $125 million — of the transaction, with an additional $125 million in deferred consideration and up to $40
• $400 million — ion in deferred consideration and up to $400 million in contingent consideration to be payab

Filing Documents

• tmo-20251029.htm (8-K) — 45KB
• thermofisherscientifictoac.htm (EX-99.1) — 25KB
• image_0.jpg (GRAPHIC) — 4KB
• image_1.jpg (GRAPHIC) — 62KB
• 0000097745-25-000156.txt ( ) — 398KB
• tmo-20251029.xsd (EX-101.SCH) — 5KB
• tmo-20251029_def.xml (EX-101.DEF) — 21KB
• tmo-20251029_lab.xml (EX-101.LAB) — 41KB
• tmo-20251029_pre.xml (EX-101.PRE) — 22KB
• tmo-20251029_htm.xml (XML) — 12KB

01 Other Events

Item 8.01 Other Events On October 29, 2025, Thermo Fisher Scientific Inc. ("Thermo Fisher") issued a press release announcing the execution of a definitive agreement to acquire Clario Holdings, Inc. ("Clario") for approximately $8.875 billion in cash at the closing of the transaction, with an additional $125 million in deferred consideration and up to $400 million in contingent consideration to be payable following the closing. The transaction is expected to be completed by the middle of 2026 and is subject to customary closing conditions and regulatory approvals. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that involve a number of risks and uncertainties. Words such as "believes," "anticipates," "plans," "expects," "seeks," "estimates," and similar expressions are intended to identify forward-looking statements, but other statements that are not historical facts may also be deemed to be forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: any natural disaster, public health crisis or other catastrophic event; the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of economic and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; the effect of laws and regulations governing government contracts; the possibility that expected benefits related to recent or pending acquisitions, including the proposed acquisition of Clario, may not materialize as expected; the proposed acquisition of Clario being timely completed, if completed at all; regulatory approvals required for the transaction not being timely obtained, if obtained at all, or being obtained subject to conditions; Clario's business experiencing disruptions as a result of the acquisition or due to transaction-related uncertainty or other factors making it more difficult to maintain relationships with employees, customers, other business partners or governmental entities; difficulty retaining key employees; the outcome of any legal proceedings related to the proposed acquisition of Clario; and the parties being unable to successfully impl

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release of Thermo Fisher Scientific Inc., dated October 29, 2025 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. THERMO FISHER SCIENTIFIC INC. Date: October 29, 2025 By: /s/ Thomas B. Shropshire Thomas B. Shropshire Senior Vice President and General Counsel 3

View Full Filing

View this 8-K filing on SEC EDGAR